Cumberland Pharmaceuticals
CPIX
21 hedge funds and large institutions have $4.77M invested in Cumberland Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
1,700% more call options, than puts
Call options by funds: $72K | Put options by funds: $4K
14% more capital invested
Capital invested by funds: $4.2M → $4.77M (+$568K)
4.07% more ownership
Funds ownership: 12.93% → 17% (+4.1%)
5% less funds holding
Funds holding: 22 → 21 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.3K |
| 2 |
Millennium Management
New York
|
+$11.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.86K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.52K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
True Capital Management
San Francisco,
California
|
-$27.1K |
| 2 |
Renaissance Technologies
New York
|
-$24.5K |
| 3 |
BlackRock
New York
|
-$20.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$18.5K |
| 5 |
Two Sigma Investments
New York
|
-$11.9K |
CPIX Hedge Fund Activity: Q1 2023 in Review
21 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2023, worth a combined $4.77M — up 14% from $4.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CPIX and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $25.3K. The largest seller was True Capital Management, exiting entirely with an estimated $27.1K sold.
- 21 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2023, down from 22 in Q4 2022.
- Funds reported $4.77M of Cumberland Pharmaceuticals stock for Q1 2023, up 14% quarter-over-quarter.
- 2 funds opened new Cumberland Pharmaceuticals positions in Q1 2023 and 3 closed out, a net change of -1 holder.
- The largest Cumberland Pharmaceuticals buyer in Q1 2023 was Susquehanna International Group, an estimated $25.3K added.
- The largest Cumberland Pharmaceuticals seller in Q1 2023 was True Capital Management, an estimated $27.1K sold.
Based on aggregated 13F filings for Q1 2023.